In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry Eyes NDI Notification Common Ground With Gottlieb-Led FDA

This article is powered by The Rose Sheet

Executive Summary

CHPA and CRN look forward to working with FDA to develop a path for the identification of pre-DSHEA ingredients, but say the FDA’s revised draft guidance for new dietary ingredient notifications still hampers innovation.


Related Content

US Supplement Market Growth: Is The Industry In Its Own Way?
FDA Plans For Soy Health Claims, Pyridoxamine's Use Questioned By CRN, NPA
GAO Memory Supplement Review Recalls FDA's Regulatory Challenges
FDA Waits For NDI Notifications Increase On Tail Of 'No Objection' Uptick
Hatch Question, Gottlieb Response Speak Volumes About DSHEA Reliance
Supplement NDI Notification Guidance Cruel To Firms On Animal Testing
Revised NDI Notification Draft Guidance Shrinks Divide Between FDA And Industry
DSHEA Sheds Little Light On Distinguishing Old From New Ingredients
FDA Revision Of NDI Draft Guidance Starts With Grandfathered List





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts